News Column

Study Results from University of Bologna Broaden Understanding of Hormones (Optical biosensor analysis in studying new synthesized bicalutamide...

July 2, 2014



Study Results from University of Bologna Broaden Understanding of Hormones (Optical biosensor analysis in studying new synthesized bicalutamide analogs binding to androgen receptor)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting out of Bologna, Italy, by NewsRx editors, research stated, "Bicalutamide (Casodex®) is a non-steroidal anti-androgen drug used in the treatment of prostate cancer, which represents the second most common malignancy diagnosed in men worldwide. In this work, we analyze the ability of some novel bicalutamide analogs to bind the androgen receptor, by using an optical biosensor."

Our news journalists obtained a quote from the research from the University of Bologna, "Androgen receptor was covalently immobilized on a carboxy methyl dextran matrix. The immobilized receptor chip was then used for the binding experiments of the bicalutamide analogs. The ®-bicalutamide dissociation constant was in good agreement to the value reported in literature obtained by using radiolabeled targets. Most of the new synthesized compounds showed higher androgen receptor binding level, when compared to the reference. Our results clearly indicate that the surface plasmon resonance (SPR) technique offers many advantages with respect to other available technologies in terms of studying biomolecular interactions."

According to the news editors, the research concluded: "Moreover, this study provides an effective methodology for determining the binding affinity of novel chemical entities for the isolated androgen receptor, thus excluding possible off-target interactions occurring in conventional cell-based techniques."

For more information on this research see: Optical biosensor analysis in studying new synthesized bicalutamide analogs binding to androgen receptor. Journal of Pharmaceutical and Biomedical Analysis, 2014;95():151-7. (Elsevier - www.elsevier.com; Journal of Pharmaceutical and Biomedical Analysis - www.elsevier.com/wps/product/cws_home/525434)

Our news journalists report that additional information may be obtained by contacting C. Fortugno, Dept. of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy. Additional authors for this research include G. Varchi, A. Guerrini, P.A. Carrupt and C. Bertucci (see also Drugs and Therapies).

Keywords for this news article include: Italy, Europe, Bologna, Hormones, Biosensing, Bioengineering, Bionanotechnology, Nanobiotechnology, Steroid Receptors, Androgen Receptors, Drugs and Therapies, DNA Binding Proteins, Transcription Factors, Androgens and Anabolic Steroids.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters